Sangamo inks deal with Novo Nordisk
7th Sep 2005, 17:51 GMT
Sangamo BioSciences licensed some of its proprietary technology to health care giant Novo Nordisk A/S Richmond-based Sangamo said Novo Nordisk will test Sangamo's zinc finger DNA-binding protein technology to see if it is useful in protein production.
Latest news from Financial News News from myHealthcareNews.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris